Literature DB >> 23020044

Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions.

Kinga K Borowicz1, Barbara Piskorska, Barbara Stępniak, Stanisław J Czuczwar.   

Abstract

Depression is becoming a growing problem in rural areas. This psychiatric disorder often accompanies epilepsy. The aim of this study was to assess the influence of fluoxetine (FXT), a commonly used antidepressant, on the protective action of two conventional antiepileptic drugs: ethosuximide (ETX) and valproate (VPA), against pentylenetetrazole (PTZ)-induced convulsions in mice. Motor coordination and long-term memory deficits induced by FXT, antiepileptic drugs alone and in combinations with FXT were assessed in the chimney test and passive-avoidance task, respectively. Brain concentrations of ETX and VPA were measured by immunofluorescence. Obtained results indicate that FXT at the dose of 15 mg/kg (i.p., 30 min before the test) significantly increased the threshold for clonic convulsions. The antidepressant drug at lower doses remained ineffective in this respect. Moreover, FXT at the highest subprotective dose (10 mg/kg, i.p.) markedly enhanced the anticonvulsant effects of VPA, but not of ETX, against PTZ-induced seizures. The interaction between FXT and VPA seems to be pharmacodynamic because the antidepressant drug did not alter the brain concentration of VPA. With regard to adverse effects, FXT, VPA, ETX, and the combinations of FXT with antiepileptic drugs, did not impair motor coordination and long-term memory in mice. In conclusion, the combination of FXT with VPA may be advantageous in the treatment of myoclonic epilepsy, and therefore it should be recommended for further study in clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23020044

Source DB:  PubMed          Journal:  Ann Agric Environ Med        ISSN: 1232-1966            Impact factor:   1.447


  5 in total

1.  Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.

Authors:  Melissa L Barker-Haliski; Kristina Johnson; Peggy Billingsley; Jennifer Huff; Laura J Handy; Rizvana Khaleel; Zhenmei Lu; Matthew J Mau; Timothy H Pruess; Carlos Rueda; Gerald Saunders; Tristan K Underwood; Fabiola Vanegas; Misty D Smith; Peter J West; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

Review 2.  Serotonin and sudden unexpected death in epilepsy.

Authors:  Alexandra N Petrucci; Katelyn G Joyal; Benton S Purnell; Gordon F Buchanan
Journal:  Exp Neurol       Date:  2019-12-19       Impact factor: 5.330

3.  A Long-Term Treatment with Arachidonyl-2'-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy.

Authors:  Marta Andres-Mach; Mirosław Zagaja; Agnieszka Haratym-Maj; Radosław Rola; Maciej Maj; Joanna Haratym; Monika Dudra-Jastrzębska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2017-04-25       Impact factor: 5.923

4.  Ketamine and its combinations with valproate and carbamazepine are ineffective against convulsions induced by atropine treatment and food intake in fasted mice.

Authors:  Neriman Gözüaçık; Aslı Zengin Türkmen; Asiye Nurten; Nurhan Enginar
Journal:  Iran J Basic Med Sci       Date:  2019-03       Impact factor: 2.699

5.  Neuronal mechanism of a BK channelopathy in absence epilepsy and dyskinesia.

Authors:  Ping Dong; Yang Zhang; Arsen S Hunanyan; Mohamad A Mikati; Jianmin Cui; Huanghe Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-14       Impact factor: 12.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.